GlaxoSmithKline released Phase II data for eltrombopag--a potential blockbuster being developed as an experimental therapy for thrombocytopenia--that demonstrated it is effective in improving platelet counts to counter the threat of spontaneous bleeding and bruising. At doses of 50 and 75 milligrams, the therapy increased the platelets by 50,000 per microlitre in 70 to 81 percent of patients compared to 11 percent of patients who received a placebo in the six-week trial. Eltrombopag was developed in a collaboration of Ligand Pharmaceuticals and GSK.
- read this report on GSK from MarketWatch